Kaufman, Jonathan L. http://orcid.org/0000-0002-5687-6429
Dimopoulos, Meletios A. http://orcid.org/0000-0001-8990-3254
White, Darrell
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Morton, James
Joy Ho, P.
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Sutherland, Heather J.
Magen, Hila http://orcid.org/0000-0002-3990-394X
Iida, Shinsuke
Kim, Jin Seok http://orcid.org/0000-0001-8986-8436
Miles Prince, H.
Cochrane, Tara
Oriol, Albert
Bahlis, Nizar J.
Chari, Ajai
O’Rourke, Lisa
Trivedi, Sonali
Casneuf, Tineke
Krevvata, Maria
Ukropec, Jon
Kobos, Rachel
Avet-Loiseau, Hervé
Usmani, Saad Z. http://orcid.org/0000-0002-5484-8731
San-Miguel, Jesus http://orcid.org/0000-0002-9183-4857
Article History
Received: 18 June 2020
Revised: 27 August 2020
Accepted: 1 October 2020
First Online: 3 November 2020
Conflict of interest
: J.L.K. consulted for Celgene, Takeda, Amgen, Bristol-Myers Squibb, Janssen, Sanofi Genzyme, and Tecnopharma; received honoraria from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi Genzyme, Takeda, and Tecnopharma; and held membership on a board of directors or advisory committee for Pharmacyclics, Incyte, TG Therapeutics, and Karyopharm. M.A.D. received honoraria from Amgen, Takeda, Celgene, Janssen, and Bristol-Myers Squibb. D.W. received honoraria from and served on advisory committees for Amgen, Antengene, Celgene, Janssen, Karyopharm, Sanofi, and Takeda. L.B. received honoraria from Celgene, Amgen, Takeda, and Janssen; served in a consulting or advisory role for Amgen, Celgene, Takeda, and Janssen; and had travel, accommodations, or other expenses paid or reimbursed by Celgene, Takeda, Janssen, Amgen, and Novartis. G.C. received honoraria from Amgen, Bristol-Myers Squibb, GlycoMimetics, Seattle Genetics, Celgene, Janssen, Takeda, and Sanofi; and received research funding from Celgene, Janssen, and Takeda. P.J.H. received investigator meeting support from Celgene, Janssen, La Jolla, and Novartis. P.M. received honoraria from and served in a consulting or advisory role for Janssen, Celgene, Amgen, and AbbVie. H.J.S. received honoraria from and served in a consulting or advisory role for Celgene, Janssen, and Amgen; and received research funding from Janssen, GlaxoSmithKline, and Karyopharm. S.I. received honoraria from Janssen, Celgene, Ono, Takeda, Bristol-Myers Squibb, Novartis, and Daiichi Sankyo; and received research funding from Janssen, Chugai, Kyowa Hakko Kirin, Ono, Takeda, Celgene, Novartis, Daiichi Sankyo, Sanofi, AbbVie, Gilead, and Bristol-Myers Squibb. H.M.P. received honoraria from Janssen and Celgene; and received research funding from Amgen and Takeda. T. Cochrane received travel expenses from Bristol-Myers Squibb, Novartis, Celgene, and Takeda. A.O. served in a consulting or advisory role for Celgene, Amgen, Janssen, and Takeda; and served on a speakers bureau for Amgen and Celgene. N.J.B. received honoraria from Celgene, Janssen, AbbVie, Sanofi, Takeda, and Amgen; served in a consulting or advisory role for Celgene, Janssen, Amgen, Sanofi, Takeda, and AbbVie; received research funding from Celgene; and had travel, accommodations, or other expenses paid or reimbursed by Celgene and Janssen. A.C. served in a consulting or advisory role for Janssen, Celgene, Novartis Pharmaceuticals, Amgen, Bristol-Myers Squibb, Karyopharm, Sanofi, Seattle Genetics, Oncopeptides, Millennium/Takeda, and Antengene; and received research funding from Janssen, Millennium/Takeda, Celgene, Amgen, Pharmacyclics, and Seattle Genetics. L.O. and T. Casneuf are employees of Janssen and hold Johnson & Johnson stock options. S.T., M.K., J.U., and R.K. are employees of Janssen. S.Z.U. served in a consulting or advisory role for Sanofi, Takeda, Celgene, Skyline, Amgen, AbbVie, Mundipharma, Seattle Genetics, and Janssen; and received grants from Sanofi, Takeda, Celgene, Skyline, Amgen, AbbVie, Mundipharma, Seattle Genetics, Janssen, Bristol-Myers Squibb, and Pharmacyclics. J.S.-M. served in a consulting or advisory role for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck Sharp & Dohme, Novartis, Takeda, Sanofi, Roche, AbbVie, GlaxoSmithKline, and Karyopharm. M.L., J.M., K.K., N.T., H.M., J.S.K., and H.A.-L. declare no competing financial interests.